Treatment intensification with incretin-based therapies is appealing given that they provide good glycaemic control with a low risk of hypoglycaemia, because of the glucose-dependent stimulation of insulin secretion and inhibition of glucagon release, and do not produce weight gain (3–6). The gene discussed is INS; the disease is Hypoglycemia.